Invitae Corporation
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Invitae Corporation (NYSE: NVTA) provides genetic testing and information services focused on hereditary conditions, reproductive health, oncology, and rare diseases. The company offers comprehensive genomic testing panels, exome sequencing, and whole-genome analysis; clinical-grade diagnostics for carrier screening, prenatal testing, and newborn screening; personalized medicine solutions including pharmacogenomics and therapy matching; and data-driven services such as genetic counseling support and population health analytics. Invitae operates globally, with primary laboratory facilities in the United States, and serves healthcare providers, patients, and biopharma partners across North America, Europe, and select Asia-Pacific markets. Founded in 2010 and headquartered in San Francisco, California, the company recently filed for Chapter 11 bankruptcy protection in February 2024 amid financial challenges, leading to a court-approved asset sale to its noteholders; this transaction resulted in a restructuring where the original equity holders were wiped out and new ownership emerged under the same Invitae name, with ongoing efforts to stabilize operations and expand service accessibility.
Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
Labcorp Finalizes Acquisition of Select Assets of Invitae
Labcorp Announces 2024 Second Quarter Results
Invitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy Patients
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
Labcorp Announces Winning Bid for Select Assets of Invitae
Invitae Enters into Agreement with Labcorp for Sale of Business
Invitae Publishes its Environmental, Social and Governance (ESG) Report
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
Genetic test maker Invitae files for bankruptcy protection in US
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
The New York Stock Exchange Will Start Delisting Invitae (NVTA) Stock
NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy
Why Is Invitae (NVTA) Stock Down 75% Today?
Medical test maker Invitae prepares for bankruptcy - WSJ
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
Is Invitae Stock a Buy Now?